Law360, New York (November 30, 2011, 4:29 PM ET) -- A Pennsylvania federal court on Tuesday dismissed a False Claims Act suit accusing Genentech Inc. of fraudulently marketing its non-Hodgkin lymphoma drug Rituxan, after the California-based biotechnology company settled the suit for $20 million.
The settlement, which calls for Genentech to pay the $20 million to the U.S., was reached last week, according to court documents. U.S. District Judge Paul Diamond dismissed the suit with prejudice, putting an end to the eight-year case.
The qui tam suit was brought by former Genentech employee John Underwood, who...
Genentech Settles FCA Suit Over Cancer Drug For $20M
To view the full article, take a free trial now.
